Barinthus Biotherapeutics（納斯達克代碼：BRNS）報告2024財年每股虧損$(1.55)，優於分析師普遍預期的$(1.67)，增長7.19%。相比去年同期虧損$(1.91)增長了18.85%。公司報告季度銷售額為$14.97百萬，符合分析師普遍預期。相比去年同期$802.00千美元的銷售額增長了1.77K%。

以上內容來自Benzinga Earnings專欄，原文如下：

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(1.55) per share which beat the analyst consensus estimate of $(1.67) by 7.19 percent. This is a 18.85 percent increase over losses of $(1.91) per share from the same period last year. The company reported quarterly sales of $14.97 million which met the analyst consensus estimate. This is a 1.77K percent increase over sales of $802.00 thousand the same period last year.